Chembio gains CDC contract for international surveillance testing
Worth $330,000, this funds the assays for studies in Peru, Haiti, India and Guatemala. The contract lasts for 12 months, giving Chembio use of its DPP Zika IgM/IgG Assay, DPP Zika/Chikungunya/Dengue IgM/IgG Combination Assay and DPP Micro Reader for the surveillance testing pilot program.
Company assays identify antibodies within a tiny (10uL) drop of blood, offering results in just 15 minutes.
“We are thrilled that CDC has chosen Chembio as a partner in the fight against the Zika virus, and we look forward to deploying our DPP Zika IgM/IgG Assay, DPP Zika/Chikungunya/Dengue IgM/IgG Combination Assay and DPP Micro Reader in India, Peru, Guatemala and Haiti,” Chembio CEO John Sperzel said. “Collectively, these four countries represent a population of nearly 1.4 billion that is experiencing local transmission of one or more of these mosquito-borne viruses. We believe this pilot program will demonstrate the ability of our DPP assays to discriminate among the viruses, identify co-infected patients and limit the spread of these serious, life-threatening diseases.”
Organizations in this story
Chembio Diagnostics, Inc. 3661 Horseblock Road Medford, NY - 11763